Navigation Links
Genomma Lab Prices Initial Public Offering and Begins Trading on Mexican Stock Exchange
Date:6/18/2008

MEXICO CITY, June 18 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma" or "the Company") today announced the pricing of its initial public offering. The offering consisted of 130,869,566 series B shares; 73.5% was placed with international investors and 26.5% was placed with Mexican investors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080618/MXW007LOGO )

Excluding the overallotment option, 23.1% of the total offering size is being sold by Invex Trust No. 414 (existing shareholders) and ZN Mexico II, L.P. (one of the Nexxus family of Funds) on a pro rata basis. The shares are now listed on the Mexican Stock Exchange (ticker symbol "LAB"), and were distributed to institutional investors in the U.S. under Rule 144A and to investors outside the U.S. and elsewhere under Reg S.

The shares were offered at a price of Ps. 16 per Series B share, equivalent to US$1.54. At such price, the aggregate value of the offering is 2.4 billion pesos (2,408 millones de pesos) or approximately 233.6 million dollars, including overallotment options.

The Company's Chairman and Chief Executive Officer, Rodrigo Herrera, stated, "We are proud to be the first over-the-counter pharmaceutical and personal care products company that is traded on the Mexican Stock Exchange. This offering was successfully completed in very challenging market conditions and we thank everyone involved for their support.

"We plan to use these funds to support our rapid growth and we look forward to many years of continued expansion in the Mexican market."

Both the international offering and the local offering were well oversubscribed. Approximately 70% of the international offering was sold in the U.S. and 30% in Europe and the rest of the world. As a result of the Company's roadshow, the international book of demand was of exceptionally high quality and consisted of a combination of dedicated healthcare specialists and dedicated Latin American investors.

UBS Investment Bank was sole global coordinator of the international offering and joint bookrunner with Merrill Lynch. The lead underwriters of the Mexican offering were IXE Casa de Bolsa, S.A. de C.V., and Casa de Bolsa Santander, S.A. de C.V.

About Genomma

Genomma Lab Internacional, S.A.B. de C.V. is a leading over-the-counter pharmaceuticals and personal care products company in Mexico. Genomma trades on the Mexican Stock Exchange under the ticker symbol LAB.

Contact:

Maria Barona

Tel: (212) 406-3691

mbarona@i-advize.com


'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Impact of Rising Gas, Food Prices Felt Globally
2. Economy, Health Care, and Gas Prices Top Issues for Women Business Owners
3. World fertilizer prices continue to soar, scientists stress need for fertilizer efficiency
4. California Green and Organic Purchasing Strong Despite Rising Prices Says Mambo Sprouts Survey
5. Consumer Reports: Some Drug Prices Can Vary By $100 or More for the Same Bottle of Pills
6. Eat Well, Save Money: BJs Offers Everyday Low Prices on Top Quality Organic Groceries, Natural Foods Versus Supermarket Prices
7. PCMA: Skyrocketing Biotech Prices Challenge Employers, Consumers
8. MIT: Rx for high drug prices
9. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
10. New Report Finds Mandatory Price Disclosure for Med Tech Would Likely Increase Prices
11. New Study Finds Slow Rate of Growth in Overall Medical Technology Prices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Russ ... announced the first national #QuackGivesBack campaign which supported local breast cancer organizations during ... franchise-wide Quack Gives Back initiative, and we’re very pleased with the ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... Suite 10.2 version gives development continuity to its innovative Unified Instance Manager ... management capacity. In addition, this new version optimizes the unattended auto-dialing system ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... STAT courier ... to be a convenient service for Texas, they are expanding their presence in Dallas. ... a hiring spree that will bring new jobs to the Dallas and Forth Worth ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- Allergy Diagnostics Market: Scope and Methodology ... used to determine the presence of allergens such ... in the samples by determining the presence of ... on global allergy diagnostics market, analyzes the current ... consists of an executive summary that provides information ...
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX ... Nationwide Children,s Hospital signed a membership ... accelerate the development of new cures. ... representing over 57 million patients globally, biopharmaceutical companies ... together to improve protocol design, site selection, patient ...
(Date:12/8/2016)... 8, 2016 True Health Diagnostics today ... laboratory services and management expertise to hospital systems ... allowing more doctors and patients to benefit from ... Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... under pressure to contain costs, have struggled to ...
Breaking Medicine Technology: